

World Journal of *Clinical Oncology*

World J Clin Oncol 2022 July 24; 13(7): 553-662



REVIEW

- 553 Nanomedicine approaches for treatment of hematologic and oncologic malignancies
Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M

MINIREVIEWS

- 567 Simple approach for the histomolecular diagnosis of central nervous system gliomas based on 2021 World Health Organization Classification
Kurdi M, Moshref RH, Katib Y, Faizo E, Najjar AA, Bahakeem B, Bamaga AK

ORIGINAL ARTICLE**Case Control Study**

- 577 Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer
Sanna V, Fedele P, Deiana G, Alicicco MG, Ninniri C, Santoro AN, Pazzola A, Fancellu A
- 587 Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome
Koumaki D, Papadakis M, Kouloumvakou S, Krasagakis K

Retrospective Cohort Study

- 599 Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy
Cox RE, Parish M, Oxencis C, Mckenna E, Thapa B, Chakrabarti S
- 609 Decreased incidence of febrile neutropenia in Michigan following masking and social distancing orders for the COVID-19 pandemic: A population based cohort study
Baracy Jr MG, Hagglund K, Kulkarni S, Afzal F, Arends K, Morris RT, Solomon LA, Aslam MF, Corey L
- 616 iCEMIGE: Integration of CELL-morphometrics, Microbiome, and GEne biomarker signatures for risk stratification in breast cancers
Mao XY, Perez-Losada J, Abad M, Rodríguez-González M, Rodríguez CA, Mao JH, Chang H
- 630 Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer
Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, Patoni C, Vladut C, Bucurica S, Costache RS, Ionita-Radu F, Jinga M

Retrospective Study

- 641 Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T

- 652 Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data
Hervás-Morón A, Domínguez-Rullán J, Santana VD, Valero M, Vallejo C, Sancho S, Fuentes JDG, López-Campos F, Gallego MC

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Oncology*, Amit Sehrawat, MBBS, MD, DrNB, MNAMS, ECMO, Assistant Professor of Medical Oncology Haematology All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand 249203, India. amit.monc@aiimsrishikesh.edu.in.

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Oncology (WJCO, World J Clin Oncol)* is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING

The *WJCO* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJCO* as 0.35.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Wen-Wen Qi; Production Department Director: Xu Guo; Editorial Office Director: Yu-Jie Ma.

NAME OF JOURNAL

World Journal of Clinical Oncology

ISSN

ISSN 2218-4333 (online)

LAUNCH DATE

November 10, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2218-4333/editorialboard.htm>

PUBLICATION DATE

July 24, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Case Control Study

Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome

Dimitra Koumaki, Marios Papadakis, Stamatoula Kouloumvakou, Konstantinos Krasagakis

Specialty type: Oncology**Provenance and peer review:**

Invited article; Externally peer reviewed.

Peer-review model: Single blind**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Chisthi MM, India; Covantsev S, Russia**A-Editor:** Yao QG, United States**Received:** February 26, 2022**Peer-review started:** February 26, 2022**First decision:** March 7, 2022**Revised:** March 18, 2022**Accepted:** June 22, 2022**Article in press:** June 22, 2022**Published online:** July 24, 2022**Dimitra Koumaki**, Department of Dermatology, University Hospital of Heraklion, Heraklion 71110, Greece**Marios Papadakis**, Department of Surgery II, University of Witten-Herdecke, Wuppertal 42283, Germany**Stamatoula Kouloumvakou**, Department of Internal Medicine, Agios Nikolaos General Hospital, Agios Nikolaos 72100, Greece**Konstantinos Krasagakis**, Department of Dermatology, University of Crete, Heraklion 71110, Greece**Corresponding author:** Marios Papadakis, MD, MSc, PhD, Consultant Physician-Scientist, Doctor, Research Scientist, Department of Surgery II, University of Witten-Herdecke, Heusnerstrasse 40, Wuppertal 42283, Germany. marios_papadakis@yahoo.gr

Abstract

BACKGROUND

Patients with atypical mole syndrome (AMS) have a 3- to 20-fold higher risk of developing malignant melanoma (MM) than individuals without. The most modifiable risk factor for developing MM is the ongoing ultraviolet exposure.

AIM

To assess awareness, knowledge, and attitudes towards sun protection among patients with MM and AMS.

METHODS

From January 2020 till December 2021, a written survey was administered to patients with MM and AMS and a control group who attended a specialist mole clinic at the Dermatology Department of the University Hospital of Heraklion in Heraklion, Crete, Greece. Demographic data and photoprotective practices, knowledge, and perceived barriers were collected. Relevant statistical analyses were performed using SPSS IBM 25.

RESULTS

In total, 121 subjects consented and participated in the survey. Their mean age was 43.92 ± 12.55 years. There were 66 (54.4%) females and 55 (45.4%) males. Forty-seven (38.8%) patients had AMS, 26 (21.5%) had a past medical history of

MM, and 48 (39.7%) attended the clinic for a full skin checkup for their naevi without having AMS or MM. Although 104 (86%) participants reported using sunscreen with the majority of them (59/121 = 48.8%) wearing sunscreen with a sun protection factor of > 50, only 22 (18.2%) patients did so every day and only 20 (16.5%) all year round. Approximately 74.4% of patients recalled having received advice on how to protect their skin from sunlight, and 73% were interested in receiving education about sun protection. The most mentioned barriers in photoprotection were concerns over adequate vitamin D and lack of time.

CONCLUSION

Despite mentioning having received adequate education in photoprotection, adherence to photoprotection practices is suboptimal in patients with MM and AMS.

Key Words: Atypical mole syndrome; Dysplastic naevi; Malignant melanoma; Photoprotection; Skin cancer

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: There are no previous studies assessing awareness, knowledge, and attitudes towards sun protection among patients with malignant melanoma (MM) and atypical mole syndrome (AMS). Our study highlights the importance to raise awareness regarding photoprotection in patients with MM and AMS to prevent skin cancer.

Citation: Koumaki D, Papadakis M, Kouloumvakou S, Krasagakis K. Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome. *World J Clin Oncol* 2022; 13(7): 587-598

URL: <https://www.wjgnet.com/2218-4333/full/v13/i7/587.htm>

DOI: <https://dx.doi.org/10.5306/wjco.v13.i7.587>

INTRODUCTION

The term atypical mole syndrome (AMS) refers to people who have multiple naevi (> 100), including some naevi larger than 8 mm in diameter with atypical features[1,2]. Patients with AMS have a 3-20 times higher risk of developing malignant melanoma (MM) than individuals without[3-6]. The most modifiable risk factor for developing MM is ongoing ultraviolet (UV) exposure[7]. Eliminating UV exposure *via* photoprotective practices is an important strategy for reducing MM risk in patients with AMS[8-10].

Through the implementation of a written survey, our aim for this study was to assess awareness, knowledge, and attitudes toward sun protection among patients with MM, those with AMS, and a control group who attended a specialist mole clinic at the dermatology department of a tertiary hospital in Greece.

MATERIALS AND METHODS

From January 2020 through December 2021, we administered a written survey to patients who attended a specialist mole clinic at the Dermatology Department of the University Hospital of Heraklion in Heraklion, Crete, Greece. Having approached 140 patients, we obtained consent from 121 patients (a response rate of 121/140 = 86.42%). The participants completed the surveys in person, and we included all the data in our analysis.

The specialist mole clinic at the Dermatology Department of the University Hospital of Heraklion is a dedicated clinic for patients at high risk of developing skin cancer, such as those who have a past medical history (PMH) of MM, non-melanoma skin cancer, or AMS or who have received immunosuppression (*e.g.*, transplant patients). All these patients undergo annual or biannual full skin checkups and receive photoprotection counselling.

The study was approved by the Ethics Committee of the University Hospital and all participants gave consent for inclusion in the study.

Survey contents

The written survey that we administered included basic demographic data, Fitzpatrick skin phototypes, medical histories, comorbidities, and collected information regarding awareness and knowledge of

Table 1 Demographic and clinical characteristics of 121 patients who were included in our study

	Patients with a PMH of MM, <i>n</i> = 26/121 (21.5%)	Patients with AMS, <i>n</i> = 47/121 (38.8%)	Control group, <i>n</i> = 48/121 (39.7%)	All participants, <i>n</i> = 121	<i>P</i> value
Mean age (\pm SD)	45.65 (\pm 12.61)	43.21 (\pm 12.61)	43.67 (\pm 12.65)	43.92 (\pm 12.55)	0.88
Gender, <i>n</i> (%)					0.39
Male	10/26 (38.5)	25/47 (53.2)	20/48 (41.7)	55/121 (45.5)	
Female	16/26 (61.5)	22/47 (46.8)	28/48 (58.3)	66/121 (54.5)	
Employment Status, <i>n</i> (%)					0.40
Student	2/26 (7.7)	3/47 (6.4)	2/48 (4.2)	7/121 (5.8)	
Employed	16/26 (61.5)	36/47 (76.6)	33/48 (68.8)	85/121 (70.2)	
Unemployed	2/26 (7.7)	4/47 (8.5)	7/48 (14.6)	13/121 (10.7)	
Retired	5/26 (19.2)	3/47 (6.4)	3/48 (6.3)	11/121 (9.1)	
Housewife	1/26 (3.8)	1/47 (2.1)	3/48 (6.3)	5/121 (4.1)	
Educational level, <i>n</i> (%)					0.61
Elementary school	9/26 (34.6)	1/47 (2.1)	3/48 (6.3)	4/121 (3.3)	
High school	0/26 (0)	20/47 (42.6)	21/48 (43.8)	50/121 (41.3)	
Technical studies	6/26 (23.1)	8/47 (17)	5/48 (10.4)	19/121 (15.7)	
University level	11/26 (42.3)	18/47 (38.3)	19/48 (39.6)	48/121 (39.7)	
Fitzpatrick skin phototype, <i>n</i> (%)					0.81
Skin type I (Always burns, does not tan)	0/26 (0)	2/47 (4.3)	2/48 (4.2)	4/121 (3.3)	
Skin type II (Burns easily, tans poorly)	10/26 (38.5)	14/47 (29.8)	15/48 (31.3)	39/121 (32.2)	
Skin type III (Tans after initial burn)	14/26 (53.8)	24/47 (51.1)	22/48 (45.8)	60/121 (49.6)	
Skin type IV (Burns minimally, tans easily)	2/26 (7.7)	7/47 (14.9)	9/48 (18.8)	18/121 (14.9)	
BMI (\pm SD)	25.07 (\pm 4.06)	26.92 (\pm 5.12)	25.58 (\pm 5.20)	25.99 (\pm 4.96)	0.281
Eye colour, <i>n</i> (%)					0.466
Dark	1/26 (3.8)	2/47 (4.3)	5/48 (10.4)	8/121 (6.6)	
Brown	16/26 (61.5)	31/47 (66)	31/48 (64.4)	78/121 (64.5)	
Blue	3/26 (11.5)	9/47 (19.1)	5/48 (10.4)	17/121 (14)	

Green	6/26 (23.1)	5/47 (10.6)	7/48 (14.6)	18/121 (18)	0.649
Natural hair color, <i>n</i> (%)					
Red	0/26 (0)	1/47 (2.1)	0/48 (0)	1/121 (0.8)	
Blond	5/26 (19.2)	6/47 (12.8)	8/48 (16.7)	19/121 (15.7)	
Brown	16/26 (61.5)	34/47 (72.3)	28/48 (58.3)	78/121 (64.5)	
Black	5/26 (19.2)	6/47 (12.8)	12/48 (25)	23/121 (19)	0.000
Number of naevi, <i>n</i> (%)					
< 25 naevi	9/26 (34.6)	0/47 (0)	23/48 (47.9)	32/121 (26.4)	
25-50 naevi	8/26 (30.8)	2/47 (4.3)	12/48 (25)	22/121 (18.2)	
50-100 naevi	3/26 (11.5)	11/47 (23.4)	7/48 (14.6)	21/121 (17.4)	
100 naevi	6/26 (23.1)	34/47 (72.3)	6/48 (12.5)	46/121 (38)	0.198
Smoking status, <i>n</i> (%)					
Current smoker	8/26 (30.8)	15/47 (31.9)	9/48 (18.8)	32/121 (26.4)	
No smoker	15/26 (57.7)	25/47 (53.2)	28/48 (58.3)	68/121 (56.2)	0.000
Ex-smoker	3/26 (11.5)	7/47 (14.9)	11/48 (22.9)	21/121 (17.4)	
Sunburn before the age of 18, <i>n</i> (%)					0.393
No	9/26 (34.6)	30/47 (63.8)	40/48 (83.3)	79/121 (65.3)	
Yes	17/26 (65.4)	17/47 (36.2)	8/48 (16.7)	42/121 (34.7)	0.35
Leisure sun exposure, <i>n</i> (%)					
No	17/26 (65.4)	31/47 (66)	38/48 (79.2)	86/121 (71.1)	0.356
Yes	9/26 (34.6)	16/47 (34)	10/48 (20.8)	35/121 (28.9)	
Occupational sun exposure, <i>n</i> (%)					0.7444
No	19/26 (73.1)	27/47 (57.4)	30/48 (62.5)	76/121 (62.8)	
Yes	7/26 (26.9)	20/47 (42.6)	18/48 (37.5)	45/121 (37.2)	
Significant time spent outdoors, <i>n</i> (%)					
No	11/26 (42.3)	24/47 (51.1)	28/48 (58.3)	63/121 (52.1)	
Yes	15/26 (57.7)	23/47 (48.9)	20/48 (42.7)	58/121 (47.9)	
Mean weeks of vacation spent before the age of 10 (\pm SD)	7.35 \pm 5.61	6.87 \pm 5	7.42 \pm 4.36	7.19 \pm 4.86	

Mean weeks of vacation spent before from the age of 11 till 18 (\pm SD)	6.12 \pm 4.27	6.38 \pm 4.44	6.94 \pm 4.20	6.55 \pm 4.29	0.740
Mean weeks of vacation spent after the age of 18 (\pm SD)	3.92 \pm 2.1	4.02 \pm 2.77	4.98 \pm 4.35	4.39 \pm 3.40	0.806

AMS: Atypical mole syndrome; PMH: Past medical history; MM: Malignant melanoma; SD: Standard deviation; BMI: Body mass index.

photoprotection measures and current sun-protective practices. The participants were asked to report any difficulties that discouraged them from practicing photoprotective measures. We administered the survey to patients after they received counseling on photoprotection from the dermatology outpatient mole clinic.

Statistical analysis

Descriptive statistics, ANOVA, Kruskal-Wallis test, *t* tests, and Pearson correlation tests were performed using SPSS version 25.0.

RESULTS

Demographic data

Of the 140 patients that we approached who attended the specialist mole clinic at the Dermatology Department of the University Hospital of Heraklion in Heraklion, Crete, Greece from January 2020 until December 2021, 121 consented to and participated in the study, making our response rate be 121/140. Their mean age was 43.92 \pm 12.55 years. There were 66 (54.4%) females and 55 (45.4%) males. Forty-seven (38.8%) patients had AMS, 26 (21.5%) had a PMH of MM, and 48 (39.7%) attended the clinic for a full skin checkup for their naevi without having AMS or MM. The main demographic and clinical characteristics of these 121 patients are summarized in Table 1. There were no statistical differences among the three groups of patients for the following demographics and clinical characteristics: Age; gender; employment status; educational level; Fitzpatrick skin phototype; body mass index; eye and natural hair color; smoking status; leisure and occupational sun exposure; significant time spent outdoors; and mean weeks of vacation spent before the age of 10, from the ages of 11 to 18, and after the age of 18. There was a significant statistical difference among the three groups regarding history of sunburn before the age of 18 ($P < 0.001$). As expected, patients with a PMH of MM more frequently had a history of sunburn before the age of 18 than the group with AMS and the control group.

Photoprotective practices

Although 104 (86%) participants reported using sunscreen, with most of them (59/121 = 48.8%) reporting wearing sunscreen with a sun protection factor (SPF) of > 50 , only 22 (18.2%) patients did so every day and only 20 (16.5%) did so all year round. Of all participants, 89 (73.6%) reported wearing sunscreen only during the summer and 94 (77.7%) only in direct sunny weather. Fifty-two patients reported reapplying sunscreen while outdoors and only a minority (37/121 = 30.58%) reported

Table 2 Sun protection practices in patients with malignant melanoma, those with atypical mole syndrome, and controls

	Patients with a PMH of MM, n = 26	Patients with AMS, n = 47	Control group, n = 48	All participants, n = 121	P value
Do you use sunscreen? n (%)					
No	5/26 (19.2)	7/47 (14.9)	5/48 (10.4)	17/121(14)	0.461
Yes	21/26 (80.8)	40/47 (85.1)	43/48 (89.8)	104/121 (86)	
If yes, which SPF sunblock rating do you use? n (%)					
< 30	2/26 (7.7)	5/47 (10.6)	9/48 (18.8)	16/121 (13.2)	0.222
≥ 30	7/26 (26.9)	10/47 (21.3)	14/48 (29.2)	31/121 (25.6)	
≥ 50	12/26 (46.2)	25/47 (53.2)	20/48 (41.7)	57/121 (47.1)	
No sunscreen use	5/26 (19.2)	7/47 (14.9)	5/48 (10.4)	17/121 (14)	
How frequently do you use sunscreen? n (%)					
Everyday	5/26 (19.2)	6/47 (12.8)	11/48 (22.9)	22/121 (18.2)	0.663
Most days	4/26 (15.4)	13/47 (27.7)	10/48 (20.8)	27/121 (22.3)	
Occasionally	11/26 (42.3)	18/47 (38.3)	18/48 (37.5)	47/121 (38.8)	
Rarely	1/26 (3.8)	3/47 (6.4)	4/48 (8.3)	8/121 (6.6)	
No sunscreen use	5/26 (19.2)	7/47 (14.9)	5/48 (10.4)	17/121 (14)	
During which seasons do you apply sunscreen? n (%)					
Only during the summer	17/26 (65.4)	37/47 (78.7)	30/48 (62.5)	84/121 (69.4)	0.353
All year-round	4/26 (15.4)	3/47 (6.4)	13/48 (27.1)	20/121 (16.5)	
No sunscreen use	5/26 (19.2)	7/47 (14.9)	5/48 (10.4)	17/121 (14)	
In which of the following weather conditions do you apply sunscreen? n (%)					
Only in direct sunny weather	17/26 (65.4)	38/47 (80.9)	34/48 (70.8)	89/121 (73.6)	0.606
Both sunny and cloudy weather	4/26 (15.4)	2/47 (4.3)	9/48 (18.8)	15/121 (12.4)	
No sunscreen use	5/26 (19.2)	7/47 (14.9)	5/48 (10.4)	17/121 (14)	
While outdoors, do you reapply sunscreen? n (%)					
No	16/26 (61.5)	21/47 (44.7)	33/48 (68.8)	70/121 (57.9)	0.31
Yes	10/26 (38.5)	26/47 (55.3)	15/48 (31.3)	51/121 (42.1)	
Do you reapply sunscreen after swimming or perspiring heavily? n (%)					
No	14/26 (53.8)	20/47 (42.6)	28/48 (58.3)	62/121 (51.2)	0.139
Yes	12/26 (46.2)	27/47 (57.4)	20/48 (41.7)	59/121 (48.8)	
Wearing UV-protective sunglasses, n (%)					
Everyday	13/26 (50)	21/47 (44.7)	12/48 (25)	46/121 (38)	0.303
Most days	5/26 (19.2)	10/47 (21.3)	16/48 (33.3)	31/121 (25.6)	
Occasionally	2/26 (7.7)	7/47 (14.9)	13/48 (27.1)	22/121 (18.2)	
Rarely	1/26 (3.8)	4/47 (8.5)	4/48 (8.3)	9/121 (7.4)	
Never	5/26 (19.2)	5/47 (10.6)	3/48 (6.3)	13/121 (10.7)	
Wearing a broad-brimmed hat, n (%)					
Everyday	5/26 (19.2)	3/47 (6.4)	3/48 (6.3)	11/121 (9.1)	0.535
Most days	1/26 (3.8)	6/47 (12.8)	6/48 (12.5)	13/121 (10.7)	
Occasionally	6/26 (23.1)	14/47 (29.8)	13/48 (27.1)	33/121 (27.3)	
Rarely	7/26 (26.9)	13/47 (27.7)	6/48 (12.5)	26/121 (21.5)	

Never	7/26 (26.9)	11/47 (23.4)	20/48 (41.7)	38/121 (31.4)	
Wearing long-sleeved shirts or long pants made from tight fabric weave, <i>n</i> (%)					
Everyday	1/26 (3.8)	2/47 (4.3)	1/48 (2.1)	4/121 (3.3)	0.275
Most days	4/26 (15.4)	11/47 (23.4)	9/48 (18.8)	24/121 (19.8)	
Occasionally	7/26 (26.9)	13/47 (27.7)	16/48 (33.3)	36/121 (29.8)	
Rarely	5/26 (19.2)	11/47 (23.4)	12/48 (25)	28/121 (23.1)	
Never	9/26 (34.6)	10/47 (21.3)	10/48 (20.8)	29/121 (24)	
Avoiding the sun during hours of peak sunlight intensity (10:00 am to 16:00 pm), <i>n</i> (%)					
Everyday	8/26 (30.8)	9/47 (19.1)	5/48 (10.4)	22/121 (18.2)	0.492
Most days	10/26 (38.5)	20/47 (42.6)	26/48 (54.2)	56/121 (46.3)	
Occasionally	4/26 (15.4)	11/47 (23.4)	13/48 (27.1)	28/121 (23.1)	
Rarely	4/26 (15.4)	5/47 (10.6)	0/48 (0)	9/121 (7.4)	
Never	0/26 (0)	2/47 (4.3)	4/48 (8.3)	6/121 (5)	

PMH: Past medical history; MM: Malignant melanoma; AMS: Atypical mole syndrome; UV: Ultraviolet.

reapplying sunscreen after swimming or perspiring. Photoprotective practices are summarized in [Table 2](#).

Forty-six (46/121 = 38%) patients reported daily use of UV sunglasses. There was a tendency of more frequent daily use of sunglasses in the MM and AMS groups in contrast to the control group, but this was not statistically significant ($P = 0.303$). Eleven (9.1%) and four (3.3%) patients reported daily use of broad-brimmed hats and long-sleeved shirts, respectively, with no significant difference among the three groups. Only a minority of patients (22/121 = 18.2%) avoided the sun daily during peak hours of sunlight intensity.

Photoprotection education and perceived barriers

Most of the patients, 90/121 (74.4%), had been given advice on how to protect their skin from sunlight, with 86/121 (71.1%) receiving that advice from their family doctor. Photoprotection education is summarized in [Table 3](#).

One third of patients (45/121 = 37%) were given sun protection education from a health-care professional more than three times; half of them (63/121 = 52.1%) were educated from multimedia sources; and most of them (104/121 = 86%) were given written photoprotective advice.

Most of the patients (88/121 = 73%) were interested in receiving education. Eighty-eight patients (72.7%) were interested in receiving sun protection advice from a health-care worker and 74 (61.2%) were interested in receiving photoprotection advice from multimedia sources.

Half of the patients (63/121 = 52.1%) had encountered barriers that discouraged them from practicing sun protection. These barriers are summarized in [Table 4](#). A quarter of them (27/121 = 22.3%) claimed that they did not have time to practice photoprotection measures. Concerns over adequate vitamin D levels and financial concerns were reported by 28.9% and 15.7%, respectively. Only a minority reported appearance concerns (4.1%), difficulty in obtaining materials (5.8%), or previous unpleasant experiences with and bad reactions to sunscreen (7% and 0.8%, respectively). There was no statistical difference among the three groups in our study.

DISCUSSION

To the best of our knowledge, we have here presented the first study of its kind describing demographic and clinical characteristics and assessing awareness, knowledge, attitudes, and barriers toward photoprotective practices among patients with MM and AMS and a control group. We conducted our study in the city of Heraklion, Crete, Greece, which has a very high UV index and a significantly homogeneous population. Limitations of our study include the small sample of patients and the single-center location.

Our evidence indicates that adapting effective photoprotective practices, such as the daily use of high SPF sunblock, wearing a broad-brimmed hat and a long-sleeved shirt, and avoiding sun exposure between the peak hours of 10:00 a.m. to 4:00 p.m. protect against the development of skin cancer[8-12]. Therefore, assessing photoprotective education and attitudes and providing sun protection education

Table 3 Sun protection education in patients with malignant melanoma, those with atypical mole syndrome, and controls

	Patients with a PMH of MM, n = 26	Patients with AMS, n = 47	Control group, n = 48	All participants, n = 121	P value
Have you ever been given advice on how to protect your skin from sunlight? n (%)					
No	6/26 (23.1)	9/47 (19.1)	16/48 (33.3)	31/121 (25.6)	0.59
Yes	20/26 (76.9)	38/47 (80.9)	32/48 (66.7)	90/121 (74.4)	
Have you ever received sun protection education from a family doctor? n (%)					
No	6/26 (23.1)	11/47 (23.4)	18/48 (37.5)	35/121 (28.9)	0.109
Yes	20/26 (76.9)	36/47 (76.6)	30/48 (62.5)	86/121 (71.1)	
On how many occasions have you received sun protection education from a healthcare professional? n (%)					
Never	5/26 (19.2)	10/47 (21.3)	14/48 (29.2)	29/121 (24)	0.316
Once	4/26 (15.4)	5/47 (10.6)	6/48 (12.5)	15/121 (12.5)	
Twice	3/26 (11.5)	6/47 (12.8)	8/48 (16.7)	17/121 (14)	
3 times	4/26 (15.4)	5/47 (10.6)	6/48 (12.5)	15/121 (12.5)	
3 times	10/26 (38.5)	21/47 (44.7)	14/48 (29.2)	45/121 (37)	
Have you ever received sun protection education from Media (i.e., television, newspaper)? n (%)					
No	11/26 (42.3)	22/47 (46.8)	25/48 (52.1)	58/121 (47.9)	0.546
Yes	15/26 (57.57)	25/47 (53.2)	23/48 (47.9)	63/121 (52.1)	
Have you ever received written advice about sun protection? n (%)					
No	21/26 (80.8)	38/47 (80.9)	45/48 (93.8)	17/121 (14)	0.055
Yes	5/26 (19.2)	9/47 (19.1)	3/48 (6.3)	104/121 (86)	
Would you be interested in receiving education about sun protection? n (%)					
No	4/26 (15.4)	12/47 (25.5)	17/48 (35.4)	33/121 (27)	0.619
Yes	22/26 (84.6)	35/47 (74.5)	31/48 (64.6)	88/121 (73)	
Would you be interested in receiving photoprotection advice about sun protection from a healthcare worker? n (%)					
No	4/26 (15.4)	16/47 (34)	17/48 (35.4)	33/121 (27.3)	0.154
Yes	22/26 (84.6)	31/47 (66)	31/48 (64.6)	88/121 (72.7)	
Would you be interested in receiving photoprotection advice about sun protection from multimedia? n (%)					
No	11/26 (42.3)	16/41 (34)	20/48 (41.7)	47/121 (36.8)	0.693
Yes	15/26 (57.7)	31/41 (66)	28/48 (58.3)	74/121 (61.2)	

PMH: Past medical history; MM: Malignant melanoma; AMS: Atypical mole syndrome.

are both important and effective in preventing skin cancer, especially in areas with high UV indexes such as Crete, Greece.

Our survey highlighted that although most of the patients used sunscreen (104/121 = 86%), and half of them (57/121 = 47.1%) used sunscreen with an SPF of > 50, only a small proportion of them (22/121 = 18.2%) applied it daily, and the majority (84/121 = 69.4%) applied it only during the summer. Many participants reported never having worn a broad-brimmed hat (38/121 = 31.4%), a long-sleeved shirt, or long pants (29/121 = 24%) to protect themselves from sunlight. There was no statistical difference among the three groups regarding sun protection practices.

Most of the patients (90/121 = 74.4%) recalled having received advice on how to protect their skin from sunlight. This shows high recall of receiving photoprotective education (this number has varied

Table 4 Perceived barriers to implementation of photoprotection practices in patients with malignant melanoma, those with atypical mole syndrome, and controls

	Patients with a PMH of MM, n = 26	Patients with AMS, n = 47	Control group, n = 48	All participants, n = 121	P value
Have any of the following barriers discouraged you from practicing sun protection? n (%)					
No	7/26 (26.9%)	27/47 (57.4%)	24/48 (50%)	58/121 (47.9%)	0.656
Yes	19/26 (73.1%)	20/47 (42.6%)	24/48 (50%)	63/121 (52.1%)	
Skepticism ("I do not believe skin cancer is a serious health threat"), n (%)					
No	22/26 (84.6%)	43/47 (91.5%)	45/48 (93.8%)	110/121 (90.9%)	0.568
Yes	4/26 (15.4%)	4/47 (8.5%)	3/48 (6.3%)	11/121 (9.1%)	
Hassle/lack of time, n (%)					
No	21/26 (80.8%)	35/47 (74.5%)	38/48 (79.2%)	94/121 (77.7%)	0.639
Yes	5/26 (19.2%)	12/47 (25.5%)	10/48 (20.8%)	27/121 (22.3%)	
Concerns over adequate Vitamin D, n (%)					
No	20/26 (76.9%)	34/47 (72.3%)	32/48 (66.7%)	86/121 (71.1%)	0.486
Yes	6/26 (23.1%)	13/47 (27.7%)	16/48 (33.3%)	35/121 (28.9%)	
Cost/financial concerns, n (%)					
No	25/26 (96.2%)	38/47 (80.9%)	39/48 (81.3%)	102/121 (84.3%)	0.810
Yes	1/26 (3.8%)	9/47 (19.1%)	9/48 (18.8%)	19/121 (15.7%)	
Appearance ("I do not like how using sun protection will make me look"), n (%)					
No	24/26 (92.3%)	44/47 (93.6%)	48/48 (100%)	116/121 (95.9%)	0.090
Yes	2/26 (7.7%)	3/47 (6.4%)	0/48 (0%)	5/121 (4.1%)	
Difficulty obtaining materials (sunscreen, sunglasses, hats, etc), n (%)					
No	25/26 (96.2%)	44/47 (93.6%)		114/121 (94.2%)	0.962
Yes	1/26 (3.8%)	3/47 (6.4%)		7/121 (5.8%)	
Sunscreen is uncomfortable or unpleasant, n (%)					
No	22/26 (84.6%)	43/48 (91.5%)	47/48 (97.9%)	112/121 (93%)	0.149
Yes	4/26 (15.4%)	4/48 (8.5%)	1/48 (2.1%)	9/121 (7%)	
Previous "bad" reaction to sunscreen (please specify), n (%)					
No	25/26 (96.2%)	47/47 (100%)	48/48 (100%)	120/121 (99.2%)	0.765
Yes	1/26 (3.8%)	0/47 (0%)	0/48 (0%)	1/121 (0.8%)	
None/no barriers have discouraged me, n (%)					
No	14/26 (53.8%)	21/121 (44.7%)	23/48 (47.9%)	58/121 (47.9%)	0.840
Yes	12/26 (46.2%)	26/121 (55.3%)	25/48 (52.1%)	63/121 (52.1%)	

PMH: Past medical history; MM: Malignant melanoma; AMS: Atypical mole syndrome.

from 27.5% to 96% in previous papers). Our survey highlights that, despite recalling having received adequate photoprotection education, the implementation of sun protective practices in all the three groups remained suboptimal. Our study showed that adherence to photoprotective practices did not correlate with education level. Previous studies have documented that a lack of post-secondary education was correlated with a reduced adoption of sun protective behaviors[13-18].

Several barriers regarding photoprotection have been reported in the literature. In our cohort, the three most-cited barriers were "concerns over adequate vitamin D" (35/121 = 28.9%), "hassle/lack of

time" (27/121 = 22.3%), and "cost/financial concerns" (19/121 = 15.7%). Only the barrier "lack of time" was consistent with previous studies[19-23].

We also found that 72.7% of the subjects expressed interest in receiving photoprotection advice from a health-care worker and 61.2% from multimedia sources. This indicates that patients might prefer receiving verbal advice from a health-care professional, and that electronic devices might also play a crucial role in relevant education[24-27]. However, the use of multimedia methods in educating people on photoprotective practices may be inefficient for older patients.

Our study has both strengths and limitations. A dermatologist assessed all participants, and the questionnaire was not only self-reported but also the patient and the dermatologist completed the questionnaire together at the same time. The dermatologist, who examined the patient, gave more accurate data. Furthermore, the design of our study involves consecutive patients who were recruited during a specific timeline. Limitations include the small sample of patients and the single-center hospital-based nature of the study. We recruited patients and controls consecutively from a tertiary referral mole clinic who were dermatology department patients. These patients might be more motivated toward skin cancer prevention knowledge and photoprotection measures, which may limit the generalizability of our results.

CONCLUSION

Considerable efforts should be made to raise awareness regarding photoprotection practices with the aim to prevent skin cancer in patients with MM and AMS.

ARTICLE HIGHLIGHTS

Research background

Patients with atypical mole syndrome (AMS) have a 3- to 20-fold higher risk of developing malignant melanoma (MM) than individuals without.

Research motivation

The most modifiable risk factor for developing MM is the ongoing ultraviolet exposure.

Research objectives

To assess awareness, knowledge, and attitudes towards sun protection among patients with MM and AMS.

Research methods

A written survey was administered to patients with MM, those with AMS, and a control group who attended a specialist mole clinic in Heraklion in Greece.

Research results

In total 121 subjects participated in the study. Their mean age was 43.92 ± 12.55 years. There were 66 (54.4%) females and 55 (45.4%) males. Forty-seven (38.8%) patients had AMS, 26 (21.5%) had a past medical history (PMH) of MM, and 48 (39.7%) attended the clinic for a full skin checkup for their naevi without having AMS or MM. 104 (86%) participants reported using sunscreen. Approximately 74.4% of patients recalled having received advice on how to protect their skin from sunlight. The most mentioned barriers in photoprotection were concerns over adequate vitamin D and lack of time.

Research conclusions

Despite mentioning having received adequate education in photoprotection, adherence to photoprotection practices is suboptimal in patients with MM and AMS.

Research perspectives

Larger prospective studies could be performed comparing awareness, knowledge, and attitudes towards photoprotection among patients with MM and AMS before and after receiving education in photoprotection.

FOOTNOTES

Author contributions: Koumaki D, Papadakis M, and Krasagakis K contributed to designing the study; Koumaki D

contributed to collecting and analyzing the data, and writing the paper; Papadakis M contributed to analyzing the data; Kouloumvakou S contributed to collecting the data; Koumaki D, Papadakis M, and Krasagakis K contributed to revising and approving the paper.

Institutional review board statement: The study was approved by the institutional review board of the University Hospital of Heraklion, Greece.

Informed consent statement: All patients gave informed consent.

Conflict-of-interest statement: All authors declare no conflict of interest for this article.

Data sharing statement: The datasets used for analysis are available from the corresponding author upon reasonable request.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Greece

ORCID number: Marios Papadakis 0000-0002-9020-874X.

S-Editor: Wang LL

L-Editor: Wang TQ

P-Editor: Wang LL

REFERENCES

- 1 **Elder DE.** Dysplastic naevi: an update. *Histopathology* 2010; **56**: 112-120 [PMID: 20055909 DOI: 10.1111/j.1365-2559.2009.03450.x]
- 2 **Schäfer T,** Merkl J, Klemm E, Wichmann HE, Ring J; KORA Study Group. The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000. *J Invest Dermatol* 2006; **126**: 1490-1496 [PMID: 16645597 DOI: 10.1038/sj.jid.5700269]
- 3 **Kang S,** Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. *Arch Dermatol* 1994; **130**: 999-1001 [PMID: 8053717]
- 4 **Olsen CM,** Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. *Cancer Prev Res (Phila)* 2010; **3**: 233-245 [PMID: 20086181 DOI: 10.1158/1940-6207.CAPR-09-0108]
- 5 **Gandini S,** Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. *Eur J Cancer* 2005; **41**: 28-44 [PMID: 15617989 DOI: 10.1016/j.ejca.2004.10.015]
- 6 **Haenssle HA,** Mogrably N, Ngassa A, Buhl T, Emmert S, Schön MP, Rosenberger A, Bertsch HP. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas. *JAMA Dermatol* 2016; **152**: 291-298 [PMID: 26536613 DOI: 10.1001/jamadermatol.2015.3775]
- 7 **Kozma B,** Eide MJ. Photocarcinogenesis: an epidemiologic perspective on ultraviolet light and skin cancer. *Dermatol Clin* 2014; **32**: 301-313, viii [PMID: 24891053 DOI: 10.1016/j.det.2014.03.004]
- 8 **Green AC,** Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol* 2011; **29**: 257-263 [PMID: 21135266 DOI: 10.1200/JCO.2010.28.7078]
- 9 **King L.** A criteria-validated sun-exposure questionnaire to evaluate skin cancer prevention campaigns. *Br J Dermatol* 2017; **176**: 298-299 [PMID: 28244102 DOI: 10.1111/bjd.15135]
- 10 **Gallagher RP,** Rivers JK, Lee TK, Bajdik CD, McLean DI, Coldman AJ. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. *JAMA* 2000; **283**: 2955-2960 [PMID: 10865273 DOI: 10.1001/jama.283.22.2955]
- 11 **Ghiasvand R,** Weiderpass E, Green AC, Lund E, Veierød MB. Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. *J Clin Oncol* 2016; **34**: 3976-3983 [PMID: 27621396 DOI: 10.1200/JCO.2016.67.5934]
- 12 **Watts CG,** Drummond M, Goumas C, Schmid H, Armstrong BK, Aitken JF, Jenkins MA, Giles GG, Hopper JL, Mann GJ, Cust AE. Sunscreen Use and Melanoma Risk Among Young Australian Adults. *JAMA Dermatol* 2018; **154**: 1001-1009 [PMID: 30027280 DOI: 10.1001/jamadermatol.2018.1774]
- 13 **Traboulsi D,** Potok OV, Ruzycki SM, Surmanowicz P, Hardin J, Khokhar B, Rabi DM, Hazlewood G, Mydlarski PR. Skin cancer knowledge and photoprotective practices of organ transplant recipients. *Clin Transplant* 2019; **33**: e13524 [PMID: 30860618 DOI: 10.1111/ctr.13524]
- 14 **Coughlin CC,** Pérez M, Kumar MG, Jeffe DB, Bayliss SJ, Sternhell-Blackwell K. Skin cancer risk education in pediatric solid organ transplant patients: an evaluation of knowledge, behavior, and perceptions over time. *Pediatr Transplant* 2017; **21** [PMID: 27804197 DOI: 10.1111/ptr.12817]
- 15 **Villani A,** Fabbrocini G, Costa C, Scalvenzi M. Awareness on sun protection behavior among melanoma and nonmelanoma skin cancer patients: An Italian tertiary cancer center experience. *Dermatol Ther* 2021; **34**: e14728 [PMID: 33381874 DOI: 10.1007/s12229-021-10000-0]

10.1111/dth.14728]

- 16 **Thet Z**, Lam AK, Ng SK, Aung SY, Han T, Ranganathan D, Borg J, Pepito C, Khoo TK. Comparison of skin cancer awareness and sun protection behaviours between renal transplant recipients and patients with glomerular disease treated with immunosuppressants. *Nephrology (Carlton)* 2021; **26**: 294-302 [PMID: 34308553 DOI: 10.1111/nep.13840]
- 17 **Meyer N**, Pruvost-Balland C, Bourdon-Lanoy E, Maubec E, Avri MF. Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. *J Eur Acad Dermatol Venereol* 2007; **21**: 520-525 [PMID: 17373981 DOI: 10.1111/j.1468-3083.2006.02019.x]
- 18 **Suppa M**, Cazzaniga S, Fargnoli MC, Naldi L, Peris K. Knowledge, perceptions and behaviours about skin cancer and sun protection among secondary school students from Central Italy. *J Eur Acad Dermatol Venereol* 2013; **27**: 571-579 [PMID: 22356655 DOI: 10.1111/j.1468-3083.2012.04484.x]
- 19 **Wang SQ**, Dusza SW. Assessment of sunscreen knowledge: a pilot survey. *Br J Dermatol* 2009; **161** Suppl 3: 28-32 [PMID: 19775354 DOI: 10.1111/j.1365-2133.2009.09446.x]
- 20 **Dadlani C**, Orlow SJ. Planning for a brighter future: a review of sun protection and barriers to behavioral change in children and adolescents. *Dermatol Online J* 2008; **14**: 1 [PMID: 19061583]
- 21 **Argyriadou S**, Makridis D, Lygidakis H, Apazidis G, Gagalis G. Knowledge and behaviour of tourists towards the sun, as studied in a region of northern Greece. *Rural Remote Health* 2005; **5**: 367 [PMID: 16248761]
- 22 **Abdul Kadir WD**, Jamil A, Shaharir SS, Md Nor N, Abdul Gafor AH. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity. *Lupus* 2018; **27**: 1287-1295 [PMID: 29665756 DOI: 10.1177/0961203318770016]
- 23 **Garbe C**, Buettner PG. Predictors of the use of sunscreen in dermatological patients in Central Europe. *Prev Med* 2000; **31**: 134-139 [PMID: 10938213 DOI: 10.1006/pmed.2000.0681]
- 24 **Lawler S**, Sugiyama T, Owen N. Sun exposure concern, sun protection behaviors and physical activity among Australian adults. *Cancer Causes Control* 2007; **18**: 1009-1014 [PMID: 17641981 DOI: 10.1007/s10552-007-9041-5]
- 25 **Thomas CL**, Fernandez-Peñas P. Experience of skin cancer and contact with health professionals is associated with increased skin cancer knowledge, but not sun safety knowledge or behaviour. *J Eur Acad Dermatol Venereol* 2017; **31**: e338-e340 [PMID: 28107579 DOI: 10.1111/jdv.14133]
- 26 **Jones B**, Oh C, Corkery E, Hanley R, Egan CA. Attitudes and perceptions regarding skin cancer and sun protection behaviour in an Irish population. *J Eur Acad Dermatol Venereol* 2007; **21**: 1097-1101 [PMID: 17714132 DOI: 10.1111/j.1468-3083.2007.02209.x]
- 27 **Firooz A**, Amin-Nejad R, Bouzari N, Nafar M, Firoozan A, Mahdavi-Mazdeh M. Sun protection in Iranian kidney transplant recipients: knowledge, attitude and practice. *J Eur Acad Dermatol Venereol* 2007; **21**: 754-757 [PMID: 17567302 DOI: 10.1111/j.1468-3083.2006.02059.x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

